Effects of losartan and enalapril at different doses on cardiac and renal interstitial matrix in spontaneously hypertensive rats

Clinical and Experimental Hypertension

Volumn 25, Issue 7, 2003, Pages 427-441

  Rizzoni, Damiano ^a   Rodella, Luigi ^a   Porteri, Enzo ^a   Rezzani, Rita ^a   Sleiman, Intissar ^a   Paiardi, Silvia ^a   Guelfi, Daniele ^a   De Ciuceis, Carolina ^a   Boari, Gianluca E M ^a   Bianchi, Rossella ^a   Agabiti Rosei, Enrico ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

ACE inhibitors; Angiotensin II; Enalapril; Hypertrophy; Interstitial matrix; Losartan; Metalloproteinases

Indexed keywords

COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GELATINASE A; GELATINASE B; LOSARTAN; MATRIX METALLOPROTEINASE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEART LEFT VENTRICLE; HYPERTENSION; INTERSTITIUM; KIDNEY STRUCTURE; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ZYMOGRAPHY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY WEIGHT; COLLAGEN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; HEART; HEART VENTRICLES; KIDNEY; LOSARTAN; MATRIX METALLOPROTEINASES; ORGAN SIZE; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 10744223350     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.1081/CEH-120024986     Document Type: Article

References (34)

1. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT, Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 1990; 67:1355-1364.
2. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC, Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV, Mendelsohn FAO, Motz WH, Mulvany MJ, Strauer BE. Remodeling and reparation of the cardiovascular system. JACC 1992; 20:3-16.
3. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26:809-820.
4. Rizzoni D, Porteri E, Piccoli A, Castellano M, Bettoni G, Muiesan ML, Pasini G, Guelfi D, Mulvany MJ, Agabiti Rosei E. Effects of losartan and enalapril on small artery structure in hypertensive rats. Hypertension 1998; 32:305-310.
5. Mezzano S, Ruiz-Ortega M, Egidio I. Angiotensin II and renal fibrosis. Hypertension 2001; 38(Pt2):635-638.
6. Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 1996; 50:684-692.
7. Mannisto TK, Karvonen KE, Kerola TV, Ryhanen LJ. Inhibitory effect of the angiotensin converting enzyme inhibitors captopril and enalapril on the conversion of procollagen to collagen. J Hypertens 2001; 19:1835-1839.
8. Thomas CV, Mytsi L, Coker BA, Zettner JL, Handy JR, Crumbley AJ, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998; 976:1708-1715.
9. Tronc FT, Mallat Z, Lehoux S, Wassef M, Esposito B, Tedgui A. Role of matrix metalloproteinases in blood flow-induced arterial enlargement. Interaction with NO. Arterioscler Thromb Vasc Biol 2000; 20:e120-e126.
10. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension: role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries Circ Res 1991; 69:107-117.
11. Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension 1996; 28:269-275.
12. Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 2001; 37(Part 2):490-496.
13. Brilla CG, Zhou G, Matsubara L, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83:1771-1779.
14. 1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000; 35:1197-1202.
15. Schwartzkopff B, Brehm M, Mundhenke M, Strauer BE. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000; 36:220-225.
16. Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens 1991; 9:3-15.
17. Brilla CG. Renin-angiotensin system mediated mechanisms: cardioreparation and cardioprotection. Br Heart J 2000; 84:18-19.
18. Pathak M, Sarkar A, Vellaichamy E, Sen S. Role of myocytes in myocardial collagen production. Hypertension 2001; 37:833-840.
19. Dostal DE. Regulation of cardiac collagen. Angiotensin and cross-talk with local growth factors. Hypertension 2001; 37:841-844.
20. Rizzoni D, Castellano M, Porteri E, Bettoni G, Muiesan ML, Cinelli A, Agabiti Rosei E. Effects of low and high doses of fosinopril on the structure and function of resistance arteries. Hypertension 1995; 26:118-123.
21. Kabour A, Henegar JR, Devinemi VR, Janicki JS. Prevention of angiotensin II-induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat. Cardiovasc Res 1995; 29:543-548.
22. Kaneko K, Susic D, Nunez E, Frohlich ED. Losartan reduces cardiac mass and improves coronary flow reserve in the spontaneously hypertensive rat. J Hypertens 1996; 14:645-653.
23. Gohlke P, Linz W, Schölkens A, Wiemer G, Unger T. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1996; 28:397-402.
24. Lundie MJ, Friberg P, Line RL, Adams MA. Long-term inhibition of the renin-angiotensin system in genetic hypertension: analysis of the impact on blood pressure and cardiovascular structural changes. J Hypertens 1997; 15:339-348.
25. Fornes P, Richer C, Vacher E, Bruneval P, Giudicelli JF. Losartan protective effects in stroke-prone spontaneously hypertensive rats persists durably after treatment withdrawal. J Cardiovasc Pharmacol 1993; 22:305-313.
26. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102:1342-1345.
27. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, Diez J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98:535-540.
28. Francischetti A, Ono H, Frohlich ED. Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension 1988; 31:795-801.
29. Casellas D, Benhamed S, Artuso A, Jover B. Candesartan and progression of preglomerular lesions in L-NAME hypertensive rats. J Am Soc Nephrol 1999; 10:S230-S233.
30. Michel JB, Xu Y, Blot S, Philippe M, Chatellier G. Improved survival in rats administered L-NAME due to converting enzyme inhibition. J Cardiovasc Pharmacol 1996; 28:142-148.
31. Peterson JT, Li H, Dillon L, Bryant JW. Evolution of matrix metalloproteinases and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 2000; 43:307-315.
32. Li YY, Feldman AM, Sun Y, McTieman CF. Differential expression of tissue inhibitor of metalloproteinases in the failing human heart. Circulation 1998; 98:1728-1734.
33. Rajavashisth TB, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, Fishbein MC, Kaul S, Cercek B, Sharifi B, Shah PK. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques. Evidence for activation by proinflammatory mediators. Circulation 1999; 99:3103-3109.
34. Li YY, McTiernan CF, Feldman AM. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res 1999; 42:162-172.